Proposal of a concept and design of a randomized phase III trial investigating the survival effect of para-aortic lymphadenectomy in endometrial cancer

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 2, 2014, Pages 312-316

  Watari, Hidemichi ^a   Todo, Yukiharu ^b   Kang, Sokbom ^c   Odagiri, Tetsuji ^a   Sakuragi, Noriaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c National Cancer Center   (South Korea)

Author keywords

Endometrial cancer; Lymphadenectomy; Prospective study; SEPAL study; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPHADENECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; STUDY DESIGN; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; AORTA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; PELVIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STANDARDS; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; AORTA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; PELVIS; RESEARCH DESIGN; SURVIVAL RATE;

EID: 84898006871     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12305     Document Type: Article

References (17)

1. National Comprehensive Cancer. Network (NCCN) guidelines for treatment of cancer (Uterine neoplasm) 2013. [Cited 4 Sept 2013.] Available from URL: http://www.nccn.org
2. Nagase S, Katabuchi H, Hiura M et al. Japan Society of Gynecologic Oncology. Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 2010; 15: 531-542.
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009; 105: 103-104.
4. Kato T, Watari H, Endo D et al. New revsed 2008 staging system for endometrial cancer produces beter discrimination in ssurvival compared with the 1988 staging system. J Surg Oncol 2012; 106: 938-941.
5. Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 2005; 96: 651-657.
6. Watari H, Mitamura T, Moriwaki M et al. Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymph-adenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer 2009; 19: 1585-1590.
7. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endo-metrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010; 375: 1165-1172.
8. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373: 125-136.
9. Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100: 1707-1716.
10. Randall ME, Filiaci VL, Muss H et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36-44.
11. Susumu N, Sagae S, Udagawa Y et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-233.
12. Miller D, Filaci V, Fleming G et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic recurrent endometrial carcinoma: a Gynecologic Oncology Group Study (GOG209). Gynecol Oncol 2012; 125: 771-773. (Abstract).
13. Todo Y, Sakuragi N, Nishida R et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 2003; 188: 1265-1272.
14. Kang S, Kang WD, Chung HH et al. Preoperative identification of a low-risk group for lymph node metastasis in endo-metrial cancer: a Korean gynecologic oncology group study. J Clin Oncol 2012; 30: 1329-1334.
15. Todo Y, Okamoto K, Hayashi M et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol 2007; 104: 623-628.
16. Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007; 8: 831-841.
17. Watanabe Y, Kitagawa R, Aoki D et al. Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group. Gynecol Oncol 2009; 115: 456-459.